Alessandra Tedeschi

19PUBLICATIONS
100CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursHumoural immunology and immunochemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Sep 30, 2026
A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignancies.

|Feb 26, 2026
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia.

Raúl Córdoba, Stephan Stilgenbauer, Paolo Ghia

|Feb 16, 2024
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel.

Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni

|Jan 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.

Enrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda

|Nov 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.

Nitin Jain, Lisa J Croner, John N Allan

|Jun 07, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

John N Allan, Ian W Flinn, Tanya Siddiqi

Pageof 4

Frequent Collaborators

6 joint publications

Annamaria Frustaci

5 joint publications

Luca Laurenti

5 joint publications

Pier Luigi Zinzani

4 joint publications

Davide Rossi